Kyverna Therapeutics · 1 day ago
Senior Director, Market Access, Health Economics, Outcomes Research & Value
United States
Full-time
Remote
Director/Executive
$280K/yr - $305K/yr
12+ years expKyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. They are seeking a Senior Director to lead the global HEOR and value strategy, ensuring alignment with corporate objectives and delivering evidence strategies that articulate the value of their therapies.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Lead the global HEOR and value strategy across pipeline and commercial assets, ensuring alignment with overall corporate, clinical, and access objectives
Develop and execute integrated evidence generation plans, including economic models, real-world evidence, patient-reported outcomes, and burden-of-disease studies to support pricing, reimbursement, and access decisions
Oversee the design, development, and maintenance of global value dossiers, HTA submissions, payer value narratives, and supporting materials across key markets
Partner closely with Clinical Development to embed HEOR endpoints and evidence requirements into clinical trial design and lifecycle planning
Collaborate with Market Access and Commercial leadership to support pricing strategy, payer engagement, launch readiness, and post-launch optimization
Serve as a senior internal advisor and escalation point on payer, HTA, and value-related questions, translating complex evidence into clear strategic recommendations
Build, lead, and mentor a high-performing HEOR and value team, including internal staff and external vendors, consultants, and academic partners
Ensure all HEOR activities are conducted in compliance with applicable regulations, industry standards, and internal governance frameworks
Monitor evolving global payer, HTA, and policy landscapes to proactively adapt evidence strategies and inform long-term planning
Qualification
Required
Bachelor's degree required
Experience in specialty or rare disease sales leadership within the biotechnology or pharmaceutical industry, with a proven record of building and scaling sales organizations in pre-launch and launch settings required
12+ years experience in HEOR, market access, or value strategy within biopharma or biotech, with demonstrated leadership at a senior or executive level
Deep understanding of global payer and HTA requirements, including experience supporting submissions and engagements in the US and key ex-US markets
Proven track record of developing and executing evidence generation strategies across clinical development and commercialization
Strong cross-functional leadership skills with the ability to influence and align senior stakeholders across the organization
Excellent strategic thinking, communication, and executive presence, with the ability to clearly articulate value to both scientific and non-scientific audiences
Successful candidates will bring strong executive presence, strategic judgment, and the ability to operate effectively in a fast-moving, high-growth environment
This role requires exceptional communication skills, a collaborative mindset, and the ability to balance high-level strategy with hands-on leadership
Comfort navigating ambiguity and contributing at the executive leadership level is essential
Preferred
Advanced degree (MBA, PhD, PharmD, or equivalent) preferred
Experience in rare disease, autoimmune disease, cell therapy, or specialty therapeutics strongly preferred
Benefits
Annual bonus
Comprehensive benefits
Participation in the Company’s stock option plan
Company
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$295MKey Investors
Oxford Finance LLCNorthpond Ventures
2025-12-17Post Ipo Equity· $100M
2025-11-03Post Ipo Debt· $25M
2024-02-08IPO
Leadership Team
Marc Grasso
Chief Financial Officer
Tom Van Blarcom
Senior Vice President, Head of Research
Recent News
2026-01-16
Company data provided by crunchbase